E-cadherin in non-tumor epithelium adjacent to oral cancer as risk marker for the development of multiple tumors

被引:12
作者
Gonzalez-Moles, M. A. [1 ]
Bravo, M. [2 ]
Ruiz-Avila, I. [3 ]
Gil-Montoya, J. A. [4 ]
Acebal, F. [5 ]
Esteban, F. [6 ]
机构
[1] Univ Granada, Sch Dent, Dept Oral Med, E-18071 Granada, Spain
[2] Univ Granada, Sch Dent, Prevent & Publ Hlth Dent Dept, E-18071 Granada, Spain
[3] Hosp Clin Univ San Cecilio, Dept Pathol, Granada, Spain
[4] Univ Granada, Sch Dent, Special Care Dent Dept, E-18071 Granada, Spain
[5] Jaen Cent Hosp, Oral & Maxillofacial Dept, Jaen 23007, Spain
[6] Virgen del Rocio Univ Hosp, Dept Otorhinolaryngol, Seville 41013, Spain
关键词
E-cadherin; Oral cancer; Precancerous field; SQUAMOUS-CELL CARCINOMA; 2ND PRIMARY TUMORS; NECK-CANCER; CLINICAL-IMPLICATIONS; FIELD CANCERIZATION; EXPRESSION; HEAD; ADHESION; INVASION; PROGRESSION;
D O I
10.1016/j.bjoms.2012.05.001
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Our aim was to find out whether the loss of E-cadherin is a risk factor for the development of multiple tumours in the oral cavity and whether it could serve as a diagnostic marker for oral premalignant fields. We studied 77 oral squamous cell carcinomas (SCC) with associated non-tumour epithelia from 61 patients. Immunohistochemical studies (antibody NHC-38) were used to investigate E-cadherin expression, which was completely lost in basal (48% of cases) and parabasal (43%) layers of non-tumour epithelia close to the tumour and in basal (47%) and parabasal (38%) layers of non-tumour epithelia distant from the tumour. In multiple tumours E-cadherin expression was significantly lower than in single tumours in the basal, parabasal layers, and the middle third of close (p = 0.002, <0.001, <0.001) and distant (p = 0.041, p <0.001, p = 0.005) non-tumour epithelia, respectively. Downregulation of E-cadherin may be valuable as a risk marker for the development of multiple tumours in the oral cavity and for the diagnosis of premalignant fields. (C) 2012 The British Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:157 / 163
页数:7
相关论文
共 26 条
  • [1] Cadherins and catenins: Role in signal transduction and tumor progression
    Behrens, J
    [J]. CANCER AND METASTASIS REVIEWS, 1999, 18 (01) : 15 - 30
  • [2] BOWIE GL, 1993, CLIN OTOLARYNGOL, V18, P196
  • [3] Second primary tumors and field cancerization in oral and oropharyngeal cancer: Molecular techniques provide new insights and definitions
    Braakhuis, BJM
    Tabor, MP
    Leemans, CR
    van der Waal, I
    Snow, GB
    Brakenhoff, RH
    [J]. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2002, 24 (02): : 198 - 206
  • [4] Braakhuis BJM, 2003, CANCER RES, V63, P1727
  • [5] Desrochers T.M., 2012, EPIGENETICS, V7
  • [6] Ki-67 expression in non-tumour epithelium adjacent to oral cancer as risk marker for multiple oral tumours
    Gonzalez-Moles, M. A.
    Bravo, M.
    Ruiz-Avila, I.
    Acebal, F.
    Gil-Montoya, J. A.
    Brener, S.
    Esteban, F.
    [J]. ORAL DISEASES, 2010, 16 (01) : 68 - 75
  • [7] Adhesion molecule CD44 expression in non-tumour epithelium adjacent to tongue cancer
    González-Moles, MA
    Bravo, M
    Ruiz-Avila, I
    Esteban, F
    Bascones-Martínez, A
    González-Moles, S
    [J]. ORAL ONCOLOGY, 2004, 40 (03) : 281 - 286
  • [8] THE MEANING AND USE OF THE AREA UNDER A RECEIVER OPERATING CHARACTERISTIC (ROC) CURVE
    HANLEY, JA
    MCNEIL, BJ
    [J]. RADIOLOGY, 1982, 143 (01) : 29 - 36
  • [9] Radiotherapy for oral cancer as a risk factor for second primary cancers
    Hashibe, M
    Ritz, B
    Le, AD
    Li, G
    Sankaranarayanan, R
    Zhang, ZF
    [J]. CANCER LETTERS, 2005, 220 (02) : 185 - 195
  • [10] PREVENTION OF 2ND PRIMARY TUMORS WITH ISOTRETINOIN IN SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK
    HONG, WK
    LIPPMAN, SM
    ITRI, LM
    KARP, DD
    LEE, JS
    BYERS, RM
    SCHANTZ, SP
    KRAMER, AM
    LOTAN, R
    PETERS, LJ
    DIMERY, IW
    BROWN, BW
    GOEPFERT, H
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (12) : 795 - 801